Reprogramming of progenitor cells in the liver to a pancreatic endocrine phenotype using a three gene cocktail and a PPAR agonist

A. Banga, L.V. Greder, J R Dutton, J Slack

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

With the long-term aim of developing a new type of therapy for diabetes, we have investigated the reprogramming of liver cells in normal mice toward a pancreatic phenotype using the gene combination Pdx1, Ngn3, MafA. CD1 mice were rendered diabetic with streptozotocin and given a single dose of Ad-PNM, an adenoviral vector containing all three genes. Ad-PNM induced hepatocytes of the liver to produce insulin, and the blood glucose became normalized. But over several weeks, the insulin-positive cells were lost and the blood glucose rose back to diabetic levels. Simultaneous administration of a peroxisome-proliferator-activated receptor agonist, WY14643, caused remission of diabetes at a lower dose of Ad-PNM and also caused the appearance of a population of insulin-secreting ductal structures in the liver. The insulin-positive ducts were stable and were able to relieve diabetes in the long term. We show that the effect of WY14643 is associated with the promotion of cell division of the ductal cells, which may increase their susceptibility to being reprogrammed toward a beta cell fate.
Original languageEnglish
Pages (from-to)19-27
Number of pages8
JournalGene Therapy
Volume21
DOIs
Publication statusPublished - Jan 2014

Fingerprint

Peroxisome Proliferator-Activated Receptors
Stem Cells
Insulin
Phenotype
Liver
Genes
Blood Glucose
Streptozocin
Cell Division
Hepatocytes
Population
Therapeutics

Cite this

Reprogramming of progenitor cells in the liver to a pancreatic endocrine phenotype using a three gene cocktail and a PPAR agonist. / Banga, A.; Greder, L.V.; Dutton, J R; Slack, J.

In: Gene Therapy, Vol. 21, 01.2014, p. 19-27.

Research output: Contribution to journalArticle

@article{b29dacf9419b4bcfad663c34f87999f6,
title = "Reprogramming of progenitor cells in the liver to a pancreatic endocrine phenotype using a three gene cocktail and a PPAR agonist",
abstract = "With the long-term aim of developing a new type of therapy for diabetes, we have investigated the reprogramming of liver cells in normal mice toward a pancreatic phenotype using the gene combination Pdx1, Ngn3, MafA. CD1 mice were rendered diabetic with streptozotocin and given a single dose of Ad-PNM, an adenoviral vector containing all three genes. Ad-PNM induced hepatocytes of the liver to produce insulin, and the blood glucose became normalized. But over several weeks, the insulin-positive cells were lost and the blood glucose rose back to diabetic levels. Simultaneous administration of a peroxisome-proliferator-activated receptor agonist, WY14643, caused remission of diabetes at a lower dose of Ad-PNM and also caused the appearance of a population of insulin-secreting ductal structures in the liver. The insulin-positive ducts were stable and were able to relieve diabetes in the long term. We show that the effect of WY14643 is associated with the promotion of cell division of the ductal cells, which may increase their susceptibility to being reprogrammed toward a beta cell fate.",
author = "A. Banga and L.V. Greder and Dutton, {J R} and J Slack",
year = "2014",
month = "1",
doi = "10.1038/gt.2013.50",
language = "English",
volume = "21",
pages = "19--27",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Research",

}

TY - JOUR

T1 - Reprogramming of progenitor cells in the liver to a pancreatic endocrine phenotype using a three gene cocktail and a PPAR agonist

AU - Banga, A.

AU - Greder, L.V.

AU - Dutton, J R

AU - Slack, J

PY - 2014/1

Y1 - 2014/1

N2 - With the long-term aim of developing a new type of therapy for diabetes, we have investigated the reprogramming of liver cells in normal mice toward a pancreatic phenotype using the gene combination Pdx1, Ngn3, MafA. CD1 mice were rendered diabetic with streptozotocin and given a single dose of Ad-PNM, an adenoviral vector containing all three genes. Ad-PNM induced hepatocytes of the liver to produce insulin, and the blood glucose became normalized. But over several weeks, the insulin-positive cells were lost and the blood glucose rose back to diabetic levels. Simultaneous administration of a peroxisome-proliferator-activated receptor agonist, WY14643, caused remission of diabetes at a lower dose of Ad-PNM and also caused the appearance of a population of insulin-secreting ductal structures in the liver. The insulin-positive ducts were stable and were able to relieve diabetes in the long term. We show that the effect of WY14643 is associated with the promotion of cell division of the ductal cells, which may increase their susceptibility to being reprogrammed toward a beta cell fate.

AB - With the long-term aim of developing a new type of therapy for diabetes, we have investigated the reprogramming of liver cells in normal mice toward a pancreatic phenotype using the gene combination Pdx1, Ngn3, MafA. CD1 mice were rendered diabetic with streptozotocin and given a single dose of Ad-PNM, an adenoviral vector containing all three genes. Ad-PNM induced hepatocytes of the liver to produce insulin, and the blood glucose became normalized. But over several weeks, the insulin-positive cells were lost and the blood glucose rose back to diabetic levels. Simultaneous administration of a peroxisome-proliferator-activated receptor agonist, WY14643, caused remission of diabetes at a lower dose of Ad-PNM and also caused the appearance of a population of insulin-secreting ductal structures in the liver. The insulin-positive ducts were stable and were able to relieve diabetes in the long term. We show that the effect of WY14643 is associated with the promotion of cell division of the ductal cells, which may increase their susceptibility to being reprogrammed toward a beta cell fate.

UR - http://www.nature.com/gt/journal/v21/n1/full/gt201350a.html

UR - http://dx.doi.org/10.1038/gt.2013.50

UR - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3880604/

U2 - 10.1038/gt.2013.50

DO - 10.1038/gt.2013.50

M3 - Article

VL - 21

SP - 19

EP - 27

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

ER -